The $6.5 billion raised by biopharmaceutical companies in the first quarter of 2025 is down nearly 20% year over year, according to a report from GlobalData. The firm says investors continue to favor later-stage companies with clinical data.
Merida Biosciences is developing antibody-like drugs designed to selectively eliminate disease-driving autoantibodies while sparing healthy components of the immune system. Graves' disease, which stems from the immune system's attack on the thyroid gland, is the startup’s lead disease target.
Health care professionals can refer patients to the best options for diagnostic imaging covered by Medicare to give more people the medical assistance they need without extra financial stress.
BridgeBio Pharma’s approval of Beyonttra comes three months after the drug landed FDA approval for cardiomyopathy caused by transthyretin amyloidosis. Our recap of recent regulatory news also spans approvals in cancer, immunology, vaccines, and more.
China has become a key piece of Foresite Capital’s investment and company formation strategy. During the J.P. Morgan Healthcare Conference, Managing Director Michael Rome shared his thoughts on why biotech in China is booming as well as therapeutic areas where he sees promising science.
Gilead Sciences is acquiring LEO Pharma’s oral small molecule inhibitors of STAT6, a protein key to two validated inflammation pathways. Other STAT6 drug developers include Kymera Therapeutics and Sanofi-partnered Recludix Pharma, which is presenting this week during the J.P. Morgan Healthcare Conference.
Ouro Medicines’ drugs deplete disease-driving immune cells, allowing the immune system to reset with naïve cells that don’t attack the body. Monograph Capital founded the startup in partnership with GSK.
The health care sector is constantly operating, so patient miscommunication can occur at any time. Find out the top-rated companies that provide medical interpretation services.
Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.
Roche is acquiring Poseida Therapeutics, a biotech developing allogeneic cell therapies for cancers and immunological indications. The two companies have been partners in hematological malignancies since 2022.
Upstream Bio will use its IPO haul to continue clinical testing of verekitug, which it contends could be a better treatment option for severe asthma compared to a commercialized Amgen and AstraZeneca drug. CAMP4 Therapeutics and CeriBell also priced IPOs to join the public markets.
Bicara Therapeutics’ IPO raised $315 million for Phase 3 testing of a bifunctional antibody drug with potential to become a first-line treatment for head and neck cancers. Zenas BioPharma and MBX Biosciences also went public; all three companies upsized their IPOs.
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
Respiratory disease and immunology are the initial focus areas of GSK’s new drug discovery partnership with Flagship Pioneering. A similar Flagship alliance with Pfizer recently announced it is pursuing novel obesity treatments.
Abiologics develops biologic drugs from building blocks not used by nature, which it says confers these proteins with properties that make for better medicines. Founded by Flagship Pioneering, the startup is focusing on developing novel biologic treatments for cancer and immunology.
Alumis’s lead drug candidate blocks TYK2, an inflammation target that’s already addressed by Sotyktu, a Bristol Myers Squibb drug approved for plaque psoriasis. Alumis plans to begin two Phase 3 tests in this indication later this year.
Johnson & Johnson is acquiring a bispecific antibody that Numab Therapeutics engineered to address two pathways associated with the inflammation and itching of atopic dermatitis. It’s J&J’s second immunology acquisition this month.
Biogen’s acquisition of Human Immunology Biosciences brings a drug candidate with potential applications in multiple immune-mediated disorders. The deal comes just prior to the scheduled presentation of clinical data in two of them.